Becton Dickinson & Co. (BDX): Price and Financial Metrics


Becton Dickinson & Co. (BDX): $245.84

-2.63 (-1.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BDX POWR Grades

  • BDX scores best on the Stability dimension, with a Stability rank ahead of 84.16% of US stocks.
  • BDX's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • BDX's current lowest rank is in the Quality metric (where it is better than 42.17% of US stocks).

BDX Stock Summary

  • BDX has a market capitalization of $70,410,383,287 -- more than approximately 96.94% of US stocks.
  • BECTON DICKINSON & CO's stock had its IPO on January 1, 1986, making it an older stock than 93.49% of US equities in our set.
  • In terms of volatility of its share price, BDX is more volatile than just 3.96% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to BECTON DICKINSON & CO, a group of peers worth examining would be ZTS, A, ABB, ETN, and BSX.
  • Visit BDX's SEC page to see the company's official filings. To visit the company's web site, go to www.bd.com.

BDX Valuation Summary

  • BDX's price/sales ratio is 3.8; this is 25.49% lower than that of the median Healthcare stock.
  • Over the past 243 months, BDX's price/sales ratio has gone up 1.8.

Below are key valuation metrics over time for BDX.

Stock Date P/S P/B P/E EV/EBIT
BDX 2023-01-30 3.8 2.8 42.0 36.9
BDX 2023-01-27 3.8 2.8 42.2 37.1
BDX 2023-01-26 3.7 2.8 41.8 36.8
BDX 2023-01-25 3.7 2.8 41.4 36.5
BDX 2023-01-24 3.7 2.8 41.2 36.4
BDX 2023-01-23 3.7 2.8 41.9 36.8

BDX Growth Metrics

    Its 4 year revenue growth rate is now at 41.33%.
  • Its 5 year net income to common stockholders growth rate is now at -29.76%.
  • Its 2 year net cashflow from operations growth rate is now at -13%.
Over the past 33 months, BDX's revenue has gone up $1,516,000,000.

The table below shows BDX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 18,870 2,634 1,689
2022-06-30 19,782 2,612 1,666
2022-03-31 20,031 3,044 1,830
2021-12-31 19,927 3,788 1,676
2021-09-30 20,248 4,647 2,002
2021-06-30 19,896 5,177 1,865

BDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BDX has a Quality Grade of C, ranking ahead of 56.62% of graded US stocks.
  • BDX's asset turnover comes in at 0.365 -- ranking 118th of 186 Medical Equipment stocks.
  • MYO, BTCY, and NURO are the stocks whose asset turnover ratios are most correlated with BDX.

The table below shows BDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.365 0.470 0.103
2021-03-31 0.347 0.469 0.092
2020-12-31 0.337 0.458 0.088
2020-09-30 0.321 0.443 0.059
2020-06-30 0.320 0.451 0.053
2020-03-31 0.333 0.462 0.062

BDX Price Target

For more insight on analysts targets of BDX, see our BDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $267.80 Average Broker Recommendation 1.58 (Moderate Buy)

BDX Stock Price Chart Interactive Chart >

Price chart for BDX

BDX Price/Volume Stats

Current price $245.84 52-week high $280.62
Prev. close $248.47 52-week low $215.90
Day low $244.04 Volume 2,117,900
Day high $250.37 Avg. volume 1,236,935
50-day MA $250.60 Dividend yield 1.48%
200-day MA $245.73 Market Cap 69.88B

Becton Dickinson & Co. (BDX) Company Bio


Becton, Dickinson and Company provides solutions which are focused on improving medication management and patient safety, supporting infection prevention practices, equipping surgical and interventional procedures, improving drug delivery, aiding anesthesiology and respiratory care, advancing cellular research and applications, enhancing the diagnosis of infectious diseases and cancers, and supporting the management of diabetes. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.


BDX Latest News Stream


Event/Time News Detail
Loading, please wait...

BDX Latest Social Stream


Loading social stream, please wait...

View Full BDX Social Stream

Latest BDX News From Around the Web

Below are the latest news stories about BECTON DICKINSON & CO that investors may wish to consider to help them evaluate BDX as an investment opportunity.

Becton, Dickinson: Management Raising Guidance Was A Pleasant Surprise

Becton, Dickinson and Company is a leading player in the medical technology and life sciences industries. Click here for our review of BDX stock and its prospects.

Seeking Alpha | February 3, 2023

BD Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity – potentially accelerating time to discovery across a wide range of disciplines including immunology, genetic disease research, and cancer and chronic disease research.

Yahoo | February 3, 2023

Becton, Dickinson quarterly results, guidance raises see Street approval

  • Becton, Dickinson's (NYSE:BDX) Q4 2022 financial results, which saw a beat on the top and bottom lines and a 2023 guidance lift, was met with approval by Street analysts.
  • Evercore ISI's Vijay Kumar, who has an outperform rating on the stock, boosted his price target to $280 from $270 (~10% upside based on Wednesday's close) given the updated guidance.
  • Joanne Wuensch, who views Becton, Dickinso...

    Seeking Alpha | February 2, 2023

Becton, Dickinson and Company (BDX) Q1 2023 Earnings Call Transcript

Becton, Dickinson and Company (NYSE:NYSE:BDX) Q1 2023 Earnings Conference Call February 2, 2023 8:00 AM ETCompany ParticipantsFrancesca DeMartino – Senior Vice President and Head-Investor…

Seeking Alpha | February 2, 2023

Becton, Dickinson and Company 2023 Q1 - Results - Earnings Call Presentation (NYSE:BDX)

The following slide deck was published by Becton, Dickinson and Company in conjunction with their 2023 Q1 earnings call.

Seeking Alpha | February 2, 2023

Read More 'BDX' Stories Here

BDX Price Returns

1-mo -5.21%
3-mo 12.42%
6-mo -4.25%
1-year -4.91%
3-year 6.37%
5-year 21.36%
YTD -3.33%
2022 5.15%
2021 1.88%
2020 -6.75%
2019 22.20%
2018 6.61%

BDX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full BDX Dividend History

Continue Researching BDX

Here are a few links from around the web to help you further your research on Becton Dickinson & Co's stock as an investment opportunity:

Becton Dickinson & Co (BDX) Stock Price | Nasdaq
Becton Dickinson & Co (BDX) Stock Quote, History and News - Yahoo Finance
Becton Dickinson & Co (BDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7757 seconds.